Trovagene Inc (TROV):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Trovagene Inc (TROV) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7333
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Trovagene Inc (Trovagene) is a clinical-stage cancer therapeutics company that focuses on improved cancer care using its technology in tumor genomics. Its lead product, PCM-075, is a polo-like kinase 1 (PLK1) inhibitor that helps treat solid tumor cancers and multiple hematologic malignancies. The company’s pipeline products include TROV-052 for the treatment of acute myeloid leukemia; and TROV-053 for the treatment of castration-resistant prostate cancer. Trovagene harnesses its proprietary Precision Cancer Monitoring (PCM) technology to analyze circulating tumor DNA (ctDNA) and clinically actionable markers for the detection and quantitation of oncogene mutations, which enable it to discover patients with possibility to respond to targeted cancer therapies. Trovagene is headquartered in San Diego, California, the US.

Trovagene Inc (TROV) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Trovagene Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Trovagene Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Trovagene Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Trovagene Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Trovagene Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Trovagene Inc, Medical Equipment, Deal Details 12
Asset Purchase 12
TrovaGene Completes Acquisition Of CLIA-Certified Lab From MultiGEN Diagnostics 12
Venture Financing 14
TrovaGene Secures USD15 Million in Venture Funding 14
Partnerships 15
Trovagene Enters Into Licensing Agreement with GenSignia IP 15
Trovagene Enters Into Licensing Agreement With Strand Life Sciences For HPV Test 16
Trovagene Enters into Agreement with Novogene 17
Trovagene Enters into Agreement for Trovera 18
Trovagene Enters into Agreement with AstraZeneca 19
Trovagene Enter into Agreements for Trovera 20
Trovagene Enters into Agreement with Boreal Genomics 21
Trovagene Enters into Agreement with USC Norris Comprehensive Cancer Center 22
Trovagene Enters into Research Agreement with University of Michigan Comprehensive Cancer Center 23
Trovagene Enters into Patent Option Agreement with Massachusetts Institute of Technology 24
TrovaGene Enters Into Licensing Agreement With Amedeo Avogadro University And Sapienza University 25
Equity Offering 26
Trovagene Raises USD18 Million in Public Offering of Shares 26
Trovagene Raises USD4.5 Million in Public Offering of Shares and Warrants 28
Trovagene Plans to Raise Funds through Public Offering of Shares upon Exercise of Warrants 30
Trovagene Raises USD7.1 Million in Private Placement of Shares and Warrants 31
Trovagene Raises USD40.3 Million in Public Offering of Shares 32
Trovagene Completes Public Offering of Shares for USD23 Million 34
Trovagene Completes Private Placement Of Shares For US$15 Million 35
Trovagene Completes Private Placement Of Units For US$4 Million 36
Trovagene Completes Exercise Of Underwriters’ Option For Public Offering Of Units For US$10.6 Million 37
Trovagene Inc – Key Competitors 38
Trovagene Inc – Key Employees 39
Trovagene Inc – Locations And Subsidiaries 40
Head Office 40
Recent Developments 41
Financial Announcements 41
Aug 03, 2018: Trovagene announces second quarter 2018 highlights and financial results 41
May 08, 2018: Trovagene Announces First Quarter 2018 Highlights and Financial Results 43
Feb 26, 2018: Trovagene Announces Fourth Quarter and Full-Year 2017 Results 44
Nov 09, 2017: Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results 46
Aug 09, 2017: Trovagene Announces Second Quarter 2017 Company Highlights and Financial Results 48
May 10, 2017: Trovagene Announces First Quarter 2017 Company Highlights and Financial Results 50
Mar 15, 2017: Trovagene Reports Fourth Quarter and Year End 2016 Financial Results 52
Corporate Communications 53
Jun 22, 2018: Trovagene Announces Senior Management Change 53
Sep 20, 2017: Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis 54
Apr 13, 2017: Trovagene Announces the Addition of Dr. Sandra Silberman to its Clinical Advisory Board 55
Legal and Regulatory 57
Jul 10, 2017: Trovagene Regains Compliance with NASDAQ Listing Requirements 57
Product News 58
Jan 03, 2018: Trovagene to Present at the Biotech Showcase Annual Conference 58
Other Significant Developments 59
Jul 12, 2017: Trovagene Announces Agreement with Novogene for NextCollect in China 59
Jun 22, 2017: Trovagene Announces Agreement with Global Biopharmaceutical Company to Utilize Trovera ctDNA Tests and Services in Cancer Clinical Trials 60
Jan 12, 2017: Trovagene Announces Broadening Network of Commercial Distributors 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Trovagene Inc, Medical Equipment, Key Facts, 2017 2
Trovagene Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Trovagene Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Trovagene Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Trovagene Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Trovagene Inc, Deals By Market, 2012 to YTD 2018 9
Trovagene Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
TrovaGene Completes Acquisition Of CLIA-Certified Lab From MultiGEN Diagnostics 12
TrovaGene Secures USD15 Million in Venture Funding 14
Trovagene Enters Into Licensing Agreement with GenSignia IP 15
Trovagene Enters Into Licensing Agreement With Strand Life Sciences For HPV Test 16
Trovagene Enters into Agreement with Novogene 17
Trovagene Enters into Agreement for Trovera 18
Trovagene Enters into Agreement with AstraZeneca 19
Trovagene Enter into Agreements for Trovera 20
Trovagene Enters into Agreement with Boreal Genomics 21
Trovagene Enters into Agreement with USC Norris Comprehensive Cancer Center 22
Trovagene Enters into Research Agreement with University of Michigan Comprehensive Cancer Center 23
Trovagene Enters into Patent Option Agreement with Massachusetts Institute of Technology 24
TrovaGene Enters Into Licensing Agreement With Amedeo Avogadro University And Sapienza University 25
Trovagene Raises USD18 Million in Public Offering of Shares 26
Trovagene Raises USD4.5 Million in Public Offering of Shares and Warrants 28
Trovagene Plans to Raise Funds through Public Offering of Shares upon Exercise of Warrants 30
Trovagene Raises USD7.1 Million in Private Placement of Shares and Warrants 31
Trovagene Raises USD40.3 Million in Public Offering of Shares 32
Trovagene Completes Public Offering of Shares for USD23 Million 34
Trovagene Completes Private Placement Of Shares For US$15 Million 35
Trovagene Completes Private Placement Of Units For US$4 Million 36
Trovagene Completes Exercise Of Underwriters' Option For Public Offering Of Units For US$10.6 Million 37
Trovagene Inc, Key Competitors 38
Trovagene Inc, Key Employees 39

List of Figures
Trovagene Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Trovagene Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Trovagene Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Trovagene Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Trovagene Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Trovagene Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Trovagene Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Trovagene Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Trovagene Inc (TROV):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pfizer Inc (PFE)-製薬・医療分野:企業M&A・提携分析
    Summary Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, …
  • Minnkota Power Cooperative Inc:企業の発電所・SWOT分析2018
    Minnkota Power Cooperative Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on ke …
  • Itausa – Investimentos Itau S.A.:企業の戦略・SWOT・財務分析
    Itausa - Investimentos Itau S.A. - Strategy, SWOT and Corporate Finance Report Summary Itausa - Investimentos Itau S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • The AES Corporation:企業の戦略・SWOT・財務情報
    The AES Corporation - Strategy, SWOT and Corporate Finance Report Summary The AES Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Navios Maritime Partners L.P.:企業のM&A・事業提携・投資動向
    Navios Maritime Partners L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Navios Maritime Partners L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Napp Pharmaceuticals Ltd:企業の戦略的SWOT分析
    Napp Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Cerus Corp (CERS)-医療機器分野:企業M&A・提携分析
    Summary Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes the INTERCEPT Blood System to enhance blood safety. INTERCEPT Blood System reduces the risk of transfusion-transmitted infections by inactivating a wide r …
  • Anhui Construction Engineering Group Co., Ltd.:企業の戦略・SWOT・財務情報
    Anhui Construction Engineering Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Anhui Construction Engineering Group Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • CHS Inc (CHSCP):企業の財務・戦略的SWOT分析
    CHS Inc (CHSCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Sociedad Minera El Brocal SAA (BROCALC1):企業の財務・戦略的SWOT分析
    Sociedad Minera El Brocal SAA (BROCALC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Drugs for Neglected Diseases initiative-製薬・医療分野:企業M&A・提携分析
    Summary Drugs for Neglected Diseases initiative (DNDi) is a research center that discovers and develops new drugs. The center develops therapeutics for the treatment of various diseases. It offers treatments which include ASAQ, ASMQ, NECT, SSG&PM and pediatric benznidazole. DNDi also offers products …
  • Advanced Proteome Therapeutics Corp (APC):製薬・医療:M&Aディール及び事業提携情報
    Summary Advanced Proteome Therapeutics Corporation (APC) is a biopharmaceutical company that focuses on the development of anticancer therapeutics that capitalizes on the properties of a natural human protein. It creates, develops and commercializes novel therapies. The company is advancing a site-s …
  • Pierre & Vacances SA (VAC):企業の財務・戦略的SWOT分析
    Pierre & Vacances SA (VAC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Techtronic Industries Co Ltd (669):企業の財務・戦略的SWOT分析
    Techtronic Industries Co Ltd (669) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • U.S. Smokeless Tobacco Company:企業の戦略・SWOT・財務情報
    U.S. Smokeless Tobacco Company - Strategy, SWOT and Corporate Finance Report Summary U.S. Smokeless Tobacco Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • EBN B.V.:石油・ガス:M&Aディール及び事業提携情報
    Summary EBN BV (EBN) is an independent oil and natural gas company that carries out exploration, production, storage and trading of oil and natural gas. The company participates in nearly all the exploration and production activities in the Netherlands through a public-private partnership model. It …
  • Hologic Inc (HOLX):医療機器:M&Aディール及び事業提携情報
    Summary Hologic Inc (Hologic) develops, manufactures and supplies diagnostic products, medical imaging systems, surgical products and light-based aesthetic and medical treatment systems. The company offers products to aid in the diagnosis of human diseases; breast imaging and related products and ac …
  • Golden Gate Capital:企業の戦略的SWOT分析
    Golden Gate Capital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Tethys Oil AB (TETY):企業の財務・戦略的SWOT分析
    Summary Tethys Oil AB (Tethys Oil) is an upstream oil and gas company that offers exploration, development and production of oil and natural gas reserves. The company holds onshore exploration licences in Lithuania and France. Tethys Oil holds Gargzdai license, Rietavas license and Raseiniai license …
  • 21st Century Oncology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary 21st Century Oncology Inc. (21st Century Oncology), a subsidiary of 21st Century Oncology Holdings, Inc., is a provider of integrated cancer care services (ICC). It operates through an integrated network of cancer treatment centers and affiliated physicians with specialization in radiation o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆